Vivos Therapeutics, Inc. (VVOS)
$0.19-$0.04 (-15.79%) Today
Latest VVOS Insider Trades
Michael C. SkaffOpen-market purchase$500K
Michael C. SkaffMichael C. SkaffMichael C. SkaffMichael C. SkaffMichael C. SkaffMichael C. SkaffMichael C. SkaffVivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 5,498,660 | $3.20M |
| Grant or award | 2 | 400,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
5 Form 4 filings on record, the earliest from Nov 27, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Bradford K. Amman - Officer | Grant or award | Common Stock | 250,000 | $0.41 | $103K | |
| Bradford K. Amman - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.41 | $61K | |
| Michael C. Skaff | Open-market purchase | Series A Convertible Preferred Stock | 859,166 | $0.58 | $500K | |
| Michael C. Skaff | Open-market purchase | Series A Convertible Preferred Stock | 1,890,164 | $0.58 | $1.10M | |
| Michael C. Skaff | Open-market purchase | Common Stock Purchase Warrant | 2,749,330 | $0.58 | $1.60M | |
| Michael C. Skaff | Open-market purchase | Common Stock | 1,044,777 | $1.34 | $1.40M | |
| Michael C. Skaff | Open-market purchase | Common Stock | 308,848 | $1.34 | $414K | |
| Michael C. Skaff | Open-market purchase | Pre-Funded Warrant | 429,957 | $1.34 | $576K | |
| Michael C. Skaff | Open-market purchase | Series A Common Stock Warrant | 1,783,582 | $1.34 | $2.39M | |
| Michael C. Skaff | Open-market purchase | Series B Common Stock Warrant | 1,783,582 | $1.34 | $2.39M | |
| Bradford K. Amman - Officer | Grant or award | Stock Option (Right to Buy) | 149,533 | $2.64 | $395K | |
| Ronald Kirk Huntsman - Officer | Grant or award | Stock Option (Right to Buy) | 315,421 | $2.64 | $833K |
Vivos Therapeutics, Inc. (VVOS) had 2 insider filings in the last 90 days, with the most recent on 2026-08-26. The full record for VVOS runs to 5 Form 4 filings, the earliest from 2024-11-27. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of VVOS were filed in the last 90 days, totaling $3.20M.
No insider sales of VVOS were filed in the last 90 days.
This page tracks VVOS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VVOS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
